Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

ImmunityBio (IBRX) Accumulated Depreciation & Amortization: 2014-2025

Historic Accumulated Depreciation & Amortization for ImmunityBio (IBRX) over the last 10 years, with Sep 2025 value amounting to $4.0 million.

  • ImmunityBio's Accumulated Depreciation & Amortization fell 11.31% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year decrease of 12.14%. This contributed to the annual value of $17.6 million for FY2024, which is 5.18% down from last year.
  • Per ImmunityBio's latest filing, its Accumulated Depreciation & Amortization stood at $4.0 million for Q3 2025, which was up 1.83% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Accumulated Depreciation & Amortization registered a high of $5.2 million during Q4 2022, and its lowest value of $3.0 million during Q1 2021.
  • Its 3-year average for Accumulated Depreciation & Amortization is $4.3 million, with a median of $4.5 million in 2024.
  • Examining YoY changes over the last 5 years, ImmunityBio's Accumulated Depreciation & Amortization showed a top increase of 61.50% in 2021 and a maximum decrease of 85.73% in 2021.
  • Over the past 5 years, ImmunityBio's Accumulated Depreciation & Amortization (Quarterly) stood at $3.6 million in 2021, then spiked by 45.37% to $5.2 million in 2022, then declined by 12.67% to $4.6 million in 2023, then decreased by 9.33% to $4.1 million in 2024, then declined by 11.31% to $4.0 million in 2025.
  • Its Accumulated Depreciation & Amortization was $4.0 million in Q3 2025, compared to $3.9 million in Q2 2025 and $3.8 million in Q1 2025.